Is GPCR or GSK more undervalued in 2026?

CirclFi compares Structure Therapeutics Inc. (GPCR) and GSK plc (GSK) using 13 institutional-grade valuation models. GPCR has a Quality of Company score of 4.1/10 while GSK scores 8.7/10.

Which is a better buy — GPCR or GSK?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do GPCR and GSK valuations compare?

GPCR at $39.34 and GSK at $50.54 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

GPCR vs GSK Valuation Comparison 2026 — Intrinsic Value Analysis

GPCR

Pharmaceutical Preparations

Structure Therapeutics Inc.

Quality

4.1

out of 10

Value Trap

SAFE

Price

$39.34

Last close

Models

10/13

Active

GSK

Pharmaceutical Preparations

GSK plc

Quality

8.7

out of 10

Value Trap

SAFE

Price

$50.54

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	GPCR Fair Value	GPCR Upside	GSK Fair Value	GSK Upside
Bayesian DCF	Intrinsic	$13.58	-65.5%	$43.74	-13.5%
Earnings Power Value	Intrinsic	$20.74	-54.4%	$56.37	+11.5%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for GPCR vs GSK — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

GPCR vs GSK — Which Stock Is More Undervalued?

GSK scores higher with a 8.7/10 quality rating vs GPCR's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Structure Therapeutics Inc. (GPCR) and GSK plc (GSK) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

GPCR currently trades at $39.34 with a QOC of 4.1/10, while GSK trades at $50.54 with a QOC of 8.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).